Oesophageal Probe Evaluation in RF Ablation of Atrial Fibrillation (OPERA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03246594 |
Recruitment Status
:
Recruiting
First Posted
: August 11, 2017
Last Update Posted
: August 11, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atrial Fibrillation | Device: Placement of oesophageal probe for temperature measurement Device: Power limitation of RF generator | Not Applicable |
The Trial will evaluate the influence of oesophageal probes in RF-ablation of atrial fibrillation regarding oesophageal complications after ablation.
200 patients will be prospectively randomised into 2 groups. The conventional group will undergo RF-Ablation of atrial fibrillation using an oesophageal probe to measure the temperature during ablation.
In the other group will receive ablation using fixed energy levels (25 Watt) at the posterior left atrial (LA) Wall without an oesophageal probe , All patients will get a gastroscopy for evaluation of oesophageal complications the day after the procedure.
All patients will have a 6 months follow up (FU) in our clinic to be reevaluated for complications (primary endpoint) and rhythm stability. (secondary endpoint)
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Oesophageal Probe Evaluation in RF Ablation of Atrial Fibrillation |
Actual Study Start Date : | July 3, 2017 |
Estimated Primary Completion Date : | February 2018 |
Estimated Study Completion Date : | August 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Esophageal Probe
Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring. Placement of oesophageal probe for temperature measurement |
Device: Placement of oesophageal probe for temperature measurement
The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
|
Experimental: No Esophageal Probe
Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring. Intervention: Power limitation of RF generator |
Device: Power limitation of RF generator
no probe utilized; Limit the RF Generator Output to 25W
|
- Oesophageal complications after RF Ablation depending on using an oesophageal probe [ Time Frame: Up to 6 months ]Incidence of oesophageal mucosa alterations in gastroscopy
- Rhythm stability after RF ablation of atrial fibrillation (AF) [ Time Frame: 6 Months ]Percentage of AF/AT recurrences in 7 day holter at 6 months

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 12 lead ECG with documented atrial fibrillation
- Indication for RF ablation of atrial fibrillation according to the recent guidelines
- Signed informed consent
- Age 18-85 years
Exclusion Criteria:
- Pregnancy or possible pregnancy without negative test within 48h prior to ablation
- Intracardiac thrombus
- Contraindication for oral anticoagulation
- Conditions, that may complicate the positioning of the oesophageal probe

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03246594
Contact: Philipp Sommer, MD | 034186525 ext 2020 | philipp.sommer@helios-kliniken.de |
Germany | |
Heart Center Leipzig | Recruiting |
Leipzig, Germany, 04289 | |
Contact: Philipp Sommer +49865 ext 252020 philipp.sommer@helios-kliniken.de |
Responsible Party: | Philipp Sommer, M.D., FHRS, FESC, Heartcenter Leipzig GmbH |
ClinicalTrials.gov Identifier: | NCT03246594 History of Changes |
Other Study ID Numbers: |
Opera-2016 |
First Posted: | August 11, 2017 Key Record Dates |
Last Update Posted: | August 11, 2017 |
Last Verified: | August 2017 |
Studies a U.S. FDA-regulated Drug Product: | No | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Philipp Sommer, Heartcenter Leipzig GmbH:
atrial fibrillation esophageal probe thermolesion |
Additional relevant MeSH terms:
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |